Ubs Asset Management Americas Inc Nurix Therapeutics, Inc. Transaction History
Ubs Asset Management Americas Inc
- $379 Billion
- Q1 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 159,530 shares of NRIX stock, worth $1.99 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
159,530
Previous 146,713
8.74%
Holding current value
$1.99 Million
Previous $2.76 Million
31.44%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding NRIX
# of Institutions
181Shares Held
74.4MCall Options Held
56.9KPut Options Held
7.9K-
Black Rock Inc. New York, NY6.82MShares$85.3 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT5.5MShares$68.8 Million2.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.42MShares$55.2 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.05MShares$50.6 Million5.06% of portfolio
-
Commodore Capital LP New York, NY3.98MShares$49.7 Million4.63% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $589M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...